Comparative Pharmacology
Head-to-head clinical analysis: BEOVU versus SUSVIMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEOVU versus SUSVIMO.
BEOVU vs SUSVIMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brolucizumab is a humanized monoclonal antibody Fab fragment that inhibits vascular endothelial growth factor (VEGF)-A, preventing its binding to VEGFR-1 and VEGFR-2 receptors, thereby reducing endothelial cell proliferation, neovascularization, and vascular permeability.
Ranibizumab is a humanized monoclonal antibody fragment that binds to and inhibits the activity of vascular endothelial growth factor A (VEGF-A), thereby reducing angiogenesis and vascular permeability.
0.5 mg (0.05 mL of 10 mg/mL solution) by intravitreal injection once every 4 weeks (monthly) for 12 months, then may be extended to once every 8 weeks (every 2 months) based on clinical response.
10 mg administered via intravitreal injection every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
None Documented
None Documented
Terminal half-life approximately 26 days (range 23-31 days) in patients with neovascular age-related macular degeneration, supporting monthly intravitreal dosing.
Terminal elimination half-life is approximately 4.9 days (range 3.5–6.7 days) in patients receiving intravitreal injections every 4 weeks. The long half-life supports sustained intravitreal VEGF suppression with monthly dosing.
Primarily metabolic clearance; <1% excreted unchanged in urine. Biliary/fecal excretion not characterized for parent drug.
Primarily metabolized in the liver via catabolism to small peptides and amino acids; renal elimination of metabolites is negligible as intact drug is not excreted renally. Biliary/fecal excretion is not a significant route. <1% of dose excreted unchanged in urine.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor